TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient's written informed consent~2. Received a single lung, bilateral lung or heart/lung transplantation between 6 weeks and 26 weeks prior to first IMP administration.~3. Male or female, 18 years of age~4. Capable of self-administration of medications~5. Capable of understanding the purpose and risk of the clinical trial~6. Received the following immunosuppressive agents and dosages for maintenance therapy:~   1. Tacrolimus and~  2. Mycophenolate mofetil (MMF) 1 to 3 g/day and~  3. Prednisone or any other steroid therapy; tapered down~7. Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration.~8. Estimated life expectancy \> 6 month~Exclusion Criteria:~1. Any previous episode of bronchiolitis obliterans (BO) or bronchiolitis obliterans syndrome (BOS) of grade 1 or higher~2. Any active invasive bacterial, viral or fungal infection~3. Received systemic maintenance immunosuppressive therapy other than listed in the inclusion criteria~4. Received any systemic or topical ciclosporin A within~5. Received any systemic or topical Rosuvastatin~6. Current mechanical ventilation~7. Received a lung re-transplantation~8. Pregnant or breast feeding woman~9. Has known hypersensitivity to ciclosporin A~10. Has a serum creatinine value of more than 265 µmol/L (3 mg/dL)~11. Unlikely to comply with visits, inhalation procedures or spirometric measurements~12. Receipt of an investigational drug within 4 weeks prior to first administration of IMP~13. Any co-existing medical condition that in the investigator's judgement~14. Psychiatric disorders or altered mental status~15. Patient was previously enrolled in the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-CsA (Type: ACTIVE_COMPARATOR): Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
- L-CsA placebo (Type: PLACEBO_COMPARATOR): Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-\>18 years old~-All patients in the urology clinic at Roswell Park who currently use a urinary drainage bag for a period of at least 7 days prior to signing consent for the study and who are expected to use a urinary drainage tube for an additional period of 4 weeks or more based on the diagnosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brody Belt (Type: EXPERIMENTAL): None
- Conventional Urinary Drainage bag (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 5 to 17 years of age~* Patients must fulfill DSM-V diagnostic criteria for autism spectrum disorder ascertained at screening, using a clinical review confirmed by the Autism Diagnosis Observation Schedule - Second edition (ADOS-2)~* Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support patients' adherence to the study procedures must be obtained for patients who are not emancipated. In accordance with Institutional Review Board (IRB) requirements, the patient will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.~* Patients are able and willing to swallow study medication suspension.~Exclusion Criteria:~* Known diagnosis of syndromal form of Autism (e.g. Rett Syndrome, Childhood Disintegrative Disorder, Fragile X Syndrome, etc.)~* Patients who cannot discontinue anti-psychotic medication~* Patients with current active seizure disorder or who have had a seizure within the last 6 months prior to screening~* Female patient who is pregnant or breastfeeding or wishing to become pregnant during study participation or unwilling to use birth control.~* Patients who have received helminthic treatment

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Trichuris suis ova (Type: ACTIVE_COMPARATOR): TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 8 doses every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age ≥18 years old;~* Diagnosis of Complex Regional Pain Syndrome (CRPS) using International Association for the Study of Pain criteria \>6 months;~* Normal liver function (AST level \<3x normal level);~* Normal kidney function (serum creatinine \<133µmol/L);~* Full blood count, haematocrit \>38%;~* Willing and able to give informed consent and of completing study questionnaires;~* Stable (no change in past two months) but suboptimal pain pharmacotherapy (i.e. additional pain control felt by patient and physician to be necessary);~* Able to attend research centre according to the visit schedule;~* Women of child-bearing potential must be using a reliable form of contraception i.e. oral contraceptives, a barrier method (condom or diaphragm), intra-uterine device or abstinence.~Exclusion Criteria:~* Optimal response to opioids, antidepressants, anticonvulsants or anti- inflammatory medications;~* Any history or indication of kidney or liver disease;~* Any history of alcohol abuse;~* Presence of diabetes;~* Subjects taking other anti-epileptic drugs, including gabapentin, pregabalin, topiramate, phenytoin, carbamazepine, and oxcarbazepine;~* Pregnancy (a serum bHCG pregnancy test will be performed as part of the initial blood panel);~* Known or suspected allergy to succinimides, ethosuximide, methsuximide (Celontin®), phensuximide;~* Any history of mental illness or disorder, which in the investigators opinion, interferes with the subjects ability to accurately report treatment response;~* Participation in other clinical trial in the 30 days prior to enrolment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Diet therapy for at least 12 weeks, or diet therapy and oral hypoglycaemic agent(s) other than SU agents for at least 12 weeks~* No previous treatment with insulin and/or SU agents~* HbA1c between 7.5% and 10.0%~* Body Mass Index (BMI) below 30.0 kg/m2~Exclusion Criteria:~* Proliferative retinopathy or maculopathy requiring acute treatment~* Impaired hepatic function~* Impaired renal function~* Cardiac diseases~* Uncontrolled hypertension~* Known hypoglycaemia unawareness or recurrent major hypoglycaemia~* Current treatment with systemic corticosteroids

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Physiologic Effects of RBC Transfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Subjects with any condition resulting in transfusion-dependent anemia~Exclusion Criteria:~* Age \<21 or \>80 years~* Pregnancy~* Acute infection in previous 4 weeks~* Active substance abuse within the past year~* Inability to give informed consent~* Inability to return for follow-up~* The presence of alloantibodies that would limit the blood bank's ability to obtain correctly aged red blood cell (RBC) units

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Fresh RBC transfusion/Storage-aged RBC transfusion (Type: ACTIVE_COMPARATOR): Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (\<10 days old) followed by a transfusion of packed RBC units of storage-aged (\>21 days old) blood.
- Storage-aged RBC transfusion/Fresh RBC transfusion (Type: ACTIVE_COMPARATOR): Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (\>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (\<10 days old).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Preschool-Aged Refractive Measurements and Amblyopia Risks Using the 2WIN-S Portable Refractor With Vision Screening by Cycloplegic Refraction in Bangkok

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* corrected visual acuity 0.1 logMAR (Snellen 20/25) or better~* Age 3-6 years old who studies in the kindergarten school that joins the study~* Parents sign informed consent form about allowing their child to join the study~Exclusion Criteria:~* other eye conditions causing visual and 2WIN-S portable refractor working disturbance such as media opacity, history of ocular surgery, strabismus, etc.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Using 2WIN-S portable refractor for amblyopia screening (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cystocele Repair With Trans Obturator Tape VS. Trans Obturator Tape Alone on Stress Urinary Incontinence.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients.~* Pure stress and/or stress-predominant mixed urinary incontinence (MUI) associated with cystocele.~* Had not undergone a previous SUI surgery.~* BMI less than 35 kg/m2~Exclusion Criteria:~* Patients out of the age limit.~* Patients refused to participate in the study.~* Severe comorbid disease (heart failure HYHA class II and above, etc.).~* Patients with a previous surgical history of transvaginal mesh.~* Patients suffering detrusor overactivity.~* Patients diagnosed with the female genital system or urinary bladder Malignancies.~* Patients diagnosed with the presence of neurological disorders that caused voiding dysfunction.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group I (TOT alone) (Type: ACTIVE_COMPARATOR): 49 Female Patients diagnosed with Stress urinary incontinence and cystocele and offered repair by Trans obturator tape procedure
- Group II (TOT+ Cystocele Repair) (Type: EXPERIMENTAL): 49 Female Patients diagnosed with Stress urinary incontinence and cystocele and offered repair by Trans obturator tape procedure concurrently with cystocele repair.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Gestational Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant~* Gestational diabetes mellitus or normal glucose tolerance~* able to exercise~Exclusion Criteria:~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- High intensity exercise (Type: EXPERIMENTAL): High intensity, short duration exercise on bike
- Moderate exercise (Type: EXPERIMENTAL): Moderate intensity exercise training on bike
- No exercise (Type: NO_INTERVENTION): No exercise, resting in the lab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* COPD with dyspnoea with Medical Research Council scale (MRC) \>1,~* No exacerbation for 6 weeks~* No bronchodilatator short action(share) (ß 2 agonist or ipratropium) within 6 hours before the respiratory evaluation and the test of reversibility.~* Patient under current treatment (ß2 long-acting agonist (LABA) or anticholinergic long-acting (LLAMA(LAMA)) or LABA-corticoid association inhaled (CSI), or triples LABA-CSI-LAMA association) stable for at least 4 weeks, and taken for at least the 1 hour the day of the visit~* Having given a written consent~Exclusion Criteria:~* Patient Under 18~* Other respiratory illness~* Clinically significant left cardiac failure~* Obesity with BMI \> 35 kg / m2)~* Unable to perform respiratory evaluations~* Contraindication to the salbutamol or to the ipratropium bromide or to one of its components~* Pregnant or breast-feeding woman~* Unable to agree~* No social security scheme

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COPD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Rehabilitation in Patients With Sarcoidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IV Sarcoidosis~* No hospitalization for respiratory distress in the 3 months preceding the inclusion~* Dyspnea on exertion~* Age over 18 years~Exclusion Criteria:~* Physical disability does not allow the creation of a rehabilitation program~* Inability to give written consent to the study~* Refusal of contraception in women of childbearing age~* Inability to participate in the entire study~* No cover by the social security system~* Inability to perform self-questionnaires etude~The trial does not include special populations include:~* Pregnant women~* Breastfeeding women~* People in emergencies~* Persons unable to consent~* Persons deprived of liberty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulmonary rehabilitation (Type: EXPERIMENTAL): Sarcoidosis patients will realize a pulmonary rehabilitation program
- Controls (Type: NO_INTERVENTION): Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effects on Diaphragmatic Electrical Activity and Respiratory Pattern of Various Levels of Assistance

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patients admitted to the ICU, intubated for acute respiratory failure, and ventilated in PS mode will be eligible for inclusion in the study.~Exclusion Criteria:~* Severe hypoxemia requiring an FIO2 \> 0.5~* hemodynamic instability (defined as the need for high doses of catecholamines namely ≥ 0.5 μg/kg min- and/or high need in volume resuscitation namely more than two litres of crystalloids in two hours-)~* oesophageal problem such as hiatal hernia, oesophageal varicosities, oesophageal surgery;~* active upper gastro-intestinal bleeding;~* known coagulation disorder;~* any other contraindication to the insertion of a naso-gastric tube;~* poor short term prognosis (death expected within the next seven days)~* age \< 18 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Left Bundle Area Versus Selective His Bundle Pacing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Over 18 years old.~2. With signed consent.~3. Pacemaker indication according to 2018 American College of Cardiology/American Heart Association/Heart Rhythm Society Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay. With one or both of the following:~   1. Symptomatic sinus node dysfunction.~  2. Symptomatic Atrioventricular (AV) block or high degree AV block.~  3. Tachy-Brady syndrome~Exclusion Criteria:~1. Previously implanted cardiac pacing devices except transvenous temporary pacemaker.~2. Patients who are eligible for appropriate cardiac resynchronization therapy(CRT) or implantable cardiovert defibrillator (ICD) implantation~3. Patients with prior septal myectomy~4. Patients with prior surgical or transcatheter aortic valve replacement~5. Anatomy precluding implant evaluated during the screening or identified during the procedure.~6. Those without ability to achieve selective His bundle pacing evaluated during the screening or identified during the procedure~7. Pregnant women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Selective or Non selective His Bundle Pacing (Type: ACTIVE_COMPARATOR): Pacemaker wires placed in Bundle of His
- Left Bundle Area Pacing (Type: ACTIVE_COMPARATOR): Pacemaker wires placed in Left Bundle Branch area

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Of Spil's Estradiol Vaginal Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal woman~* At least one subject-self-assessed moderate to severe symptom of vulvar and vaginal atrophy~* ≤ 5% superficial cells on vaginal smear cytology~* Vaginal pH \> 5.0~Exclusion Criteria:~* Consumption of estrogen alone or estrogen/progestin containing drug products.~* Allergy to estradiol or related products~* History of breast cancer and significant risk factors for endometrial cancer~* Abnormal genital bleeding

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estradiol (Type: EXPERIMENTAL): Intravaginal self-administration of study medication once daily for 14 days.
- Reference: Estradiol (Type: ACTIVE_COMPARATOR): Intravaginal self-administration of study medication once daily for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Intravaginal self-administration of study medication once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues